Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01474681
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:53.153843+00:00
Published At
2017-05-12T00:00:00+00:00
Record Updated At
2020-12-30
Results Posted At
2017-05-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myelocytic Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Chronic Lymphocytic Leukemia", "Marginal Zone Lymphoma", "Follicular Lymphomas", "Large-cell Lymphoma", "Lymphoblastic Lymphoma", "Burkitt\u0027s Lymphoma", "High Grade Lymphomas", "Mantle-cell Lymphoma", "Lymphoplasmacytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-12-30"
protocolSection.identificationModule.nctId
"NCT01474681"
protocolSection.identificationModule.officialTitle
"A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-05-12"

Study condition terms

  • Acute Myelocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Follicular Lymphomas (protocolSection.conditionsModule.conditions)
  • Large-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
  • Burkitt's Lymphoma (protocolSection.conditionsModule.conditions)
  • High Grade Lymphomas (protocolSection.conditionsModule.conditions)
  • Mantle-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.